Want to see ALVO full AI Analyst Report?
ALVO Stock Chart & Stats
$3.06
$0.02(0.65%)
At close: 4:00 PM EDT
$3.06
$0.02(0.65%)
Day’s Range― - ―
52-Week Range$2.94 - $9.25
Previous Close$3.08
Volume397.90K
Average Volume (3M)847.68K
Market Cap
$1.61B
Enterprise Value$2.53K
Total Cash (Recent Filing)$63.83M
Total Debt (Recent Filing)$1.46B
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 19, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding390,431,500
10 Day Avg. Volume655,921
30 Day Avg. Volume847,682
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-5.03
Price to Sales (P/S)2.44
P/FCF Ratio-12.49
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.00Price Target Upside30.72% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$618.98M
Bulls Say, Bears Say
Bulls Say
High And Stable Gross MarginsConsistent ~60% gross margins across recent periods reflect the inherent economics of biosimilars and provide durable unit-level profitability as volumes scale. This margin buffer supports reinvestment for launches and R&D, improving long-term ability to absorb pricing pressure and fund growth.
Commercial Traction And Global ReachGaining share on a flagship Humira biosimilar and a presence in 90+ countries indicate durable commercial capabilities and partner distribution strength. Broad geographic footprint and multiple launched products reduce dependence on any single market and support recurring revenue growth over several years.
Manufacturing Diversification With FujifilmA formal tech transfer to Fujifilm and added U.S. capacity materially reduces single-site concentration risk and strengthens supply resilience. Diversified manufacturing capacity supports timely launches and long-term commercial scale while lowering regulatory and throughput vulnerability.
Bears Say
High Leverage And Negative EquitySubstantial debt exceeding or approaching the asset base and negative equity create lasting refinancing and covenant risk. Elevated leverage increases required cash interest and limits strategic flexibility, making the company more sensitive to industry shocks and slower revenue ramps over the medium term.
Sustained Negative Cash FlowPersistent negative operating and free cash flow implies ongoing reliance on external financing to fund operations, R&D and launches. Until operations produce durable positive cash flow, the company faces recurring dilution or higher-cost debt, constraining long-term investment and margin improvement.
Interest Burden And Throughput-Driven Low Product MarginsHigh recurring interest payments materially erode operating cash available for growth, while throughput issues that compress product margins reduce sustainable gross-profit conversion. Together these structural cash and margin pressures weaken the firm's ability to self-fund and scale profitably without further remediation or capital.
Alvotech News
ALVO FAQ
What was Alvotech’s price range in the past 12 months?
Alvotech lowest stock price was $2.94 and its highest was $9.25 in the past 12 months.
What is Alvotech’s market cap?
Alvotech’s market cap is $1.61B.
When is Alvotech’s upcoming earnings report date?
Alvotech’s upcoming earnings report date is Aug 19, 2026 which is in 16 days.
How were Alvotech’s earnings last quarter?
Alvotech released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.047 by -$0.043.
Is Alvotech overvalued?
According to Wall Street analysts Alvotech’s price is currently Undervalued.
Does Alvotech pay dividends?
Alvotech does not currently pay dividends.
What is Alvotech’s EPS estimate?
Alvotech’s EPS estimate is -0.05.
How many shares outstanding does Alvotech have?
Alvotech has 390,431,500 shares outstanding.
What happened to Alvotech’s price movement after its last earnings report?
Alvotech reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.047. Following the earnings report the stock price went down -10.364%.
Which hedge fund is a major shareholder of Alvotech?
Currently, no hedge funds are holding shares in ALVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alvotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$4.00 (30.72% Upside)
$4.00 (30.72% Upside)
Blogger Sentiment
Bullish
ALVO Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.11%
Trailing 12-Months
Company Description
Alvotech
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
ALVO Company Deck
ALVO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong pipeline momentum, rising EBITDA margins, meaningful commercial traction (notably AVT02 market share), a strategic Fujifilm manufacturing partnership and constructive full-year guidance are clear positives. Offsetting these are a material Q1 revenue decline (-20% YoY) and low product margin (11%) driven by deliberate manufacturing slowdowns to address regulatory findings, along with negative operating cash flow, a modest cash balance ($64M) and substantial quarterly interest payments. The company emphasizes derisking for stronger 2027 growth, but near-term financial and regulatory execution risks remain.View all ALVO earnings summariesALVO Stock 12 Month Forecast
Average Price Target
$4.00
▲(30.72% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
1.22% Mutual Funds
0.05% Other Institutional Investors
98.24% Public Companies and
Individual Investors